CIK 0001724521 · Large accelerated filer
Arcus Biosciences, Inc.
Sign in to watch- Ticker
- RCUS
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473898435
- Phone
- (510) 694-6200
- Business address
- 3928 POINT EDEN WAY, HAYWARD, CA, 94545
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $84,810
- in 1 filing, $85K under 10b5-1 plans
Net −$84,810. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-10 | KANEKO YASUNORI Director | Grant or award · Stock Option (Right to Buy) | +38,300 | 38,300 | ||
| 2025-06-10 | Lambert Nicole Director | Grant or award | +13,300 | 37,300 | ||
| 2025-06-10 | Lambert Nicole Director | Grant or award · Stock Option (Right to Buy) | +38,300 | 38,300 | ||
| 2025-02-27 | KANEKO YASUNORI Director | Purchase | +20,000 | $10.06 | $201K | 28,400 |
| 2025-02-27 | ROSEN TERRY J Chief Executive Officer | Purchase | +19,800 | $10.18 | $201K | 2,554,160 |
| 2025-02-18 | GILEAD SCIENCES, INC. 10% owner | Purchase | +1,363,636 | $11.00 | $15.0M | 31,424,760 |
| 2025-02-10 | Markus Richard Chief Medical Officer | Grant or award | +75,193 | 75,193 | ||
| 2025-02-10 | Markus Richard Chief Medical Officer | Grant or award · Stock Option (right to buy) | +305,328 | 305,328 | ||
| 2025-01-23 | Tang Carolyn C. General Counsel | Grant or award | +37,000 | 137,623 | ||
| 2025-01-23 | Tang Carolyn C. General Counsel | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2025-01-23 | ROSEN TERRY J Chief Executive Officer | Grant or award | +165,000 | 2,534,360 | ||
| 2025-01-23 | ROSEN TERRY J Chief Executive Officer | Grant or award · Stock Option (right to buy) | +650,000 | 650,000 | ||
| 2025-01-23 | Ribas Antoni Director | Grant or award · Stock Option (right to buy) | +5,000 | 5,000 | ||
| 2025-01-23 | Jarrett Jennifer Chief Operating Officer | Grant or award | +50,000 | 213,369 | ||
| 2025-01-23 | Jarrett Jennifer Chief Operating Officer | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2025-01-23 | Goeltz II Robert C. Chief Financial Officer | Grant or award | +37,000 | 97,138 | ||
| 2025-01-23 | Goeltz II Robert C. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2025-01-23 | Azoy Alexander Chief Accounting Officer | Grant or award | +17,100 | 30,194 | ||
| 2025-01-23 | Azoy Alexander Chief Accounting Officer | Grant or award · Stock Option (right to buy) | +11,400 | 11,400 | ||
| 2025-01-23 | Lacey David L. Director | Grant or award · Stock Option (right to buy) | +5,000 | 5,000 |
Page 6 of 9 · 177 trades